Hausdorff W P, Lohse M J, Bouvier M, Liggett S B, Caron M G, Lefkowitz R J
Howard Hughes Medical Institute, Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710.
Symp Soc Exp Biol. 1990;44:225-40.
Binding of the catecholamine agonists epinephrine and norepinephrine to the beta-adrenergic receptor (BAR) rapidly activates adenylate cyclase via the stimulatory guanine nucleotide regulatory protein Gs, and results in rises in cellular levels of cAMP. However, continuous exposure to these agonists leads within minutes to a dampening of the enzymatic response. Both in vivo and in vitro studies have implicated agonist-induced phosphorylation of BAR in this process. These results include the isolation of a novel beta-adrenergic receptor kinase (BARK), which has been shown to preferentially phosphorylate receptors that are occupied by agonist when assessed in vitro. Recent studies in our laboratory have examined the desensitization process in intact cells to determine where on the receptor molecule functionally relevant phosphorylation occurs, and to identify the kinase(s) involved. In one set of studies, site-specific mutagenic techniques with the cloned gene for the human beta 2-adrenergic receptor were utilized to delete putative sites of phosphorylation by BARK and/or the cAMP-dependent protein kinase (PKA). Following expression of the mutated receptors in mammalian cells, the cells were challenged with different concentrations of agonist for 10-15 min and the functional and phosphorylation properties of the mutant receptors were then assessed. In another set of studies human A431 cells were permeabilized with low concentrations of digitonin and treated with selective inhibitors of both BARK and PKA. The cells were then exposed to desensitizing concentrations of agonist, and similar measurements performed. Taken together, the results from both sets of studies suggest that exposure of cells to low (nanomolar) concentrations of agonist leads to phosphorylation of the receptor on one or both consensus sites for PKA, and that the predominant effect of this phosphorylation on the adenylyl cyclase response is a loss in sensitivity of the receptor to further stimulation by the agonist. In contrast, exposure of cells to higher (micromolar) concentrations of agonist leads to BAR phosphorylation by both PKA and BARK, the latter on the carboxyl terminal region of the receptor. Phosphorylation of the receptor by both kinases appears to be required for the full desensitization effect seen with the high concentration of agonist, which includes both losses in sensitivity and in the maximal responsiveness of the adenylyl cyclase response upon subsequent challenge with the agonist. Such a dual kinase control of BAR phosphorylation may have important implications for understanding the regulation of desensitization under different physiological circumstances.
儿茶酚胺激动剂肾上腺素和去甲肾上腺素与β-肾上腺素能受体(BAR)结合后,通过刺激性鸟嘌呤核苷酸调节蛋白Gs迅速激活腺苷酸环化酶,导致细胞内cAMP水平升高。然而,持续暴露于这些激动剂会在几分钟内导致酶促反应减弱。体内和体外研究均表明激动剂诱导的BAR磷酸化参与了这一过程。这些结果包括分离出一种新型的β-肾上腺素能受体激酶(BARK),体外研究表明,该激酶优先磷酸化被激动剂占据的受体。我们实验室最近的研究检查了完整细胞中的脱敏过程,以确定受体分子上功能相关的磷酸化发生在何处,并确定参与的激酶。在一组研究中,利用针对人β2-肾上腺素能受体的克隆基因的位点特异性诱变技术,删除BARK和/或cAMP依赖性蛋白激酶(PKA)的假定磷酸化位点。在哺乳动物细胞中表达突变受体后,用不同浓度的激动剂刺激细胞10 - 15分钟,然后评估突变受体的功能和磷酸化特性。在另一组研究中,用低浓度的洋地黄皂苷使人类A431细胞透化,并用BARK和PKA的选择性抑制剂处理。然后使细胞暴露于脱敏浓度的激动剂,并进行类似的测量。两组研究结果共同表明,细胞暴露于低(纳摩尔)浓度的激动剂会导致受体在PKA的一个或两个共有位点上发生磷酸化,并且这种磷酸化对腺苷酸环化酶反应的主要影响是受体对激动剂进一步刺激的敏感性丧失。相反,细胞暴露于高(微摩尔)浓度的激动剂会导致PKA和BARK对BAR的磷酸化,后者发生在受体的羧基末端区域。两种激酶对受体的磷酸化似乎是高浓度激动剂产生完全脱敏作用所必需的,这种脱敏作用包括敏感性丧失以及随后用激动剂刺激时腺苷酸环化酶反应的最大反应性丧失。这种对BAR磷酸化的双激酶控制可能对理解不同生理情况下的脱敏调节具有重要意义。